Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.

Immunocytochemical staining with monoclonal antibody NCRC 11 of formalin fixed paraffin embedded tumour tissue has been studied in 444 cases of primary breast cancer with a minimum follow period of 6 years. The relationship between extent of staining, assessed on a four point scale, and patient surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, I. O., Bell, J., Todd, J. M., Williams, M., Dowle, C., Robins, A. R., Elston, C. W., Blamey, R. W., Baldwin, R. W.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002198/
https://www.ncbi.nlm.nih.gov/pubmed/3663477
_version_ 1782135705277825024
author Ellis, I. O.
Bell, J.
Todd, J. M.
Williams, M.
Dowle, C.
Robins, A. R.
Elston, C. W.
Blamey, R. W.
Baldwin, R. W.
author_facet Ellis, I. O.
Bell, J.
Todd, J. M.
Williams, M.
Dowle, C.
Robins, A. R.
Elston, C. W.
Blamey, R. W.
Baldwin, R. W.
author_sort Ellis, I. O.
collection PubMed
description Immunocytochemical staining with monoclonal antibody NCRC 11 of formalin fixed paraffin embedded tumour tissue has been studied in 444 cases of primary breast cancer with a minimum follow period of 6 years. The relationship between extent of staining, assessed on a four point scale, and patient survival has been confirmed. There are significant relationships between staining and both histological grade and oestrogen receptor status. No association has been shown between staining and lymph node stage or tumour size. Simplification of staining assessment by modification to two staining groups still allows significant separation of patients into prognostic groups and incorporation into an existing prognostic index. IMAGES:
format Text
id pubmed-2002198
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20021982009-09-10 Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Ellis, I. O. Bell, J. Todd, J. M. Williams, M. Dowle, C. Robins, A. R. Elston, C. W. Blamey, R. W. Baldwin, R. W. Br J Cancer Research Article Immunocytochemical staining with monoclonal antibody NCRC 11 of formalin fixed paraffin embedded tumour tissue has been studied in 444 cases of primary breast cancer with a minimum follow period of 6 years. The relationship between extent of staining, assessed on a four point scale, and patient survival has been confirmed. There are significant relationships between staining and both histological grade and oestrogen receptor status. No association has been shown between staining and lymph node stage or tumour size. Simplification of staining assessment by modification to two staining groups still allows significant separation of patients into prognostic groups and incorporation into an existing prognostic index. IMAGES: Nature Publishing Group 1987-09 /pmc/articles/PMC2002198/ /pubmed/3663477 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ellis, I. O.
Bell, J.
Todd, J. M.
Williams, M.
Dowle, C.
Robins, A. R.
Elston, C. W.
Blamey, R. W.
Baldwin, R. W.
Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
title Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
title_full Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
title_fullStr Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
title_full_unstemmed Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
title_short Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
title_sort evaluation of immunoreactivity with monoclonal antibody ncrc 11 in breast carcinoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002198/
https://www.ncbi.nlm.nih.gov/pubmed/3663477
work_keys_str_mv AT ellisio evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT bellj evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT toddjm evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT williamsm evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT dowlec evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT robinsar evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT elstoncw evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT blameyrw evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma
AT baldwinrw evaluationofimmunoreactivitywithmonoclonalantibodyncrc11inbreastcarcinoma

Ejemplares similares